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Abstract
X-Adrenoleukodystrophy (X-ALD) and its adult-onset, most prevalent variant adrenomyeloneuropathy (AMN) are caused by
mutations in the peroxisomal transporter of the very long-chain fatty acid ABCD1. AMN patients classically present spastic
paraparesis that can progress over decades, and a satisfactory treatment is currently lacking. Oxidative stress is an early culprit in
X-ALD pathogenesis. A combination of antioxidants halts the clinical progression and axonal damage in a murine model of
AMN, providing a strong rationale for clinical translation. In this phase II pilot, open-label study, 13 subjects with AMN were
administered a high dose of α-tocopherol, N-acetylcysteine, and α-lipoic acid in combination. The primary outcome was the
validation of a set of biomarkers for monitoring the biological effects of this and future treatments. Functional clinical scales, the
6-minute walk test (6MWT), electrophysiological studies, and cerebral MRI served as secondary outcomes. Most biomarkers of
oxidative damage and inflammation were normalized upon treatment, indicating an interlinked redox and inflammatory homeo-
stasis. Two of the inflammatory markers, MCP1 and 15-HETE, were predictive of the response to treatment. We also observed a
significant decrease in central motor conduction time, together with an improvement or stabilization of the 6MWT in 8/10
subjects. This study provides a series of biomarkers that are useful to monitor redox and pro-inflammatory target engagement
in future trials, together with candidate biomarkers that may serve for patient stratification and disease progression, which merit
replication in future clinical trials. Moreover, the clinical results suggest a positive signal for extending these studies to phase III
randomized, placebo-controlled, longer-term trials with the actual identified dose. ClinicalTrials.gov Identifier: NCT01495260
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Introduction
X-Adrenoleukodystrophy (X-ALD) is the most frequently
inherited leukodystrophy, with a minimum incidence of 1 in
14,700 live births [1]. The gene mutated in the disease
(ABCD1) encodes the ALD protein (ALDP), a peroxisomal
transporter that imports very long-chain fatty acids (VLCFA)
into the peroxisome for degradation [2, 3]. Elevated plasma
VLCFA is a pathognomonic biomarker for this disorder, al-
though it lacks predictive value for disease severity or progres-
sion [4]. Different phenotypes have been described in X-ALD.
Virtually all patients who reach adulthood develop the most
frequent phenotype, adrenomyeloneuropathy (AMN), in their
third and fourth decades of life. The initial symptoms are
limited to the spinal cord and peripheral nerves. Patients de-
velop progressive spastic paraparesis, sensory ataxia with im-
paired vibration sense, sphincter dysfunction, pain in the legs,
and impotence [5]. Neurophysiological findings reveal axonal
neuropathy and disturbances in evoked potentials [6]. Brain
magnetic resonance imaging (MRI) results are often abnor-
mal, mainly affecting the corticospinal tract [7].
Approximately 80% of patients suffer from adrenocortical in-
sufficiency [5]. Women carriers often present mild myelopa-
thy after the fourth decade of life [8]. The most severe disease
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phenotype, cerebral childhood adrenoleukodystrophy
(cALD), presents rapidly progressive inflammatory brain de-
myelination with a lethal outcome unless diagnosed early and
treated with hematopoietic bone marrow transplant [9] or the
new available hematopoietic stem cell therapy [10].
At present, there is no satisfactory treatment for patients
with AMN [11]. Oxidative stress is a major factor driving X-
ALD pathogenesis [12–17] and appears very early in life [12].
At the origin of this, redox imbalance is a combination of
increased production of mitochondrial radical oxygen species
(ROS) caused by the excess of VLCFA [18], together with a
deficient endogenous antioxidant response [13, 19]. The com-
bination of antioxidants used herein, α-tocopherol (vit E), N-
acetylcysteine (NAC), and α-lipoic acid (LA), has been
shown to be synergistic in vitro, halting the clinical progres-
sion and axonal damage in a murine model of AMN [20].
Moreover, this combination ameliorates key metabolic path-
ways contributing to the pathogenetic cascade, such as energy
production [21], mitochondrial biogenesis and respiration
[22], proteostasis [23, 24], and endoplasmic reticulum stress
[25]. These findings indicate that oxidative damage is a very
early driver of pathogenesis, whereas providing a strong ratio-
nale for clinical translation. To date, no biomarkers of disease
progression have been identified in X-ALD, as the VLCFA
levels in plasma do not correlate with the onset or severity of
symptoms. The present work contributes to filling this knowl-
edge gap.
Methods
Study Design and Subjects
This was a phase II pilot, prospective, open-label, single-
center study, which was approved by the Spanish Agency
of Medicines and Medical Devices and by the Clinical
Research Ethics Committee of Bellvitge University
Hospital and was registered at ClinicalTrials.gov
(NCT01495260). The trial was conducted in accordance
with the ethical standards of the Declaration of Helsinki.
The subjects were followed up for 2 years (8 visits).
Thirteen subjects, 12 men and 1 woman, were selected
for the study. The age of the subjects ranged from 24 to
64 years. All the subjects had a confirmed diagnosis of
AMN on the basis of elevated VLCFA levels and an
identified pathogenic variant of the ABCD1 gene. All the
subjects met all the inclusion criteria and none of the
exclusion criteria in accordance with the protocol.
Inclusion Criteria Symptomatic subjects over 18 years of age,
with confirmed diagnosis of AMN by elevation in VLCFA
and the presence of a mutation in the ABCD1 gene.
Exclusion Criteria Cerebral inflammatory disease verified with
gadolinium enhancement, cerebral disease with cognitive im-
pairment, Expanded Disability Status Scale (EDSS) > 6.5, hy-
persensitivity to compounds related to cysteine, peptic ulcer,
asthma, severe respiratory failure, impaired hepatic function,
or other basic blood and urine tests, and pregnant, lactating, or
childbearing-aged women.
Clinical and demographic data for the subjects at the initi-
ation of the study are available in Table 1. VLCFA levels and
pathogenic variants in ABCD1 of the subjects are available in
Supplemental Data (Table 1).
For statistical purposes, plasma and peripheral blood
mononuclear cells (PBMCs) from 25 healthy age- and sex-
matched individuals and cerebrospinal fluid (CSF) from 9
subjects with nonrelated diseases were used as controls.
Procedures
Because this combination of antioxidants has not, to our
knowledge, been used previously, we used 2 different doses
owing to safety considerations. Patients initially received a
lower dose A: NAC (800 mg), LA (300 mg), and vit E
(150 IU) orally daily for 2 months. After this treatment period,
a 2-month washout period was introduced, and protein oxida-
tive damage biomarkers in plasma were tested. In patients
showing normalization of biomarkers, the treatment was
restarted for 12 months at the same dose. In patients showing
no normalization of oxidative damage biomarkers, the dosage
was increased to dose B for 3 months: NAC (2400 mg), LA
(600 mg), and vit E (300 IU), single high doses already re-
ported in the literature. After this treatment period, the bio-
markers were tested again. A further washout period of
2 months ensued. If normalization of the levels was attained
with dose B, the treatment was restarted for 12 more months
with the higher dose. In the eventuality that protein oxidative
damage biomarkers were not reduced, the patient was consid-
ered a nonresponder, and the treatment was discontinued at
that point. Plasma and PBMC extractions were assessed at all
visits (Fig. 1).
Only 1 patient (patient 8) exhibited normalized oxida-
tive damage biomarkers in plasma and PBMCs with the
lower dose of antioxidants (dose A). Thus, and following
the protocol, the patient was maintained on the same treat-
ment regimen (dose A) for an additional year until the end
of the study. The remaining subjects were treated with dose
B for an additional year.
Primary Outcomes
Oxidative Protein Damage MarkersMetal-catalyzed oxidation
products: AASA (aminoadipic semialdehyde) and GSA
(glutamic semialdehyde); mixed glycoxidation/lipoxidation
products: CEL (Nepsilon-(carboxyethyl)-lysine) and CML
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(Nep s i l on - ( c a r boxyme thy l ) - l y s i n e ) ; a nd l i p i d
peroxidation-derived products: MDAL (Nepsilon-
malondialdehyde-lysine) were quantified in the plasma as
previously reported [12]. AASA, CML, CEL, and MDAL
were expressed as micromoles per mole lysine.
Oxidative DNA Damage Marker 8-Oxo-dG (7,8-dihydro-8-
oxo-2-deoxyguanosine) was tested in the urine by HPLC ac-
cording to the methodology described by Haghdoost et al.
[26]. The 8-oxo-dG content was expressed as nanogram per
milligram creatine.
The reference values for oxidative damage biomarkers
were calculated according to the sample distribution of 25
healthy individuals. The point that defines a superior moderate
outlier in the sample of controls was taken as the reference
limit (Q75 + 1.5 × IQR, Q75 = 75% percentile, IQR = inter-
quartile range).
Inflammatory Biomarkers We quantified the following mole-
cules with previously reported methods [27]: i) plasma eicos-
anoids and oxidized polyunsaturated fatty acids (AA, DHA,
PGD2, PGE2, PGF2α, 6-keto-PGF1α, 9S-HODE, 13S-
HODE, 12S-HETE, 15S-HETE, and TXB2); ii) plasma in-
flammatory cytokines, chemokines, and signalling receptors
(HGF, IL-6, IL-8, MCP1, TNF, and adiponectin); iii)
PBMC cytokines and signalling receptors (IFNA2, IL-
37, IL-4, PPARα, IL-10, IL-36A, IL-36RN, IL-13,
CCR3, CXCL5, IL-9R, and STAT1). Briefly, eicosanoids
and oxidized polyunsaturated fatty acids were measured
by a triple quadrupole mass spectrometry–based metabo-
lite quantification assay (Biocrates Life Science AG,
Innsbruck, Austria); HGF, IL-6, IL-8, MCP1, TNF, and
adiponectin were determined by immunoassays using the
Milliplex kit (Luminex xMAP Technology, EMD
Millipore Corporation, Billerica, MA), and IFNA2, IL-
37, IL-4, PPARα, IL-10, IL-36A, IL-36RN, IL-13,
CCR3, CXCL5, IL-9R, and STAT1 gene expression was
quantified by real-time PCR with Taqman® probes in
total RNA from PBMCs. We also tested neopterin in
the cerebrospinal fluid according to the methodology de-
scribed by Molero-Luis et al. [28].
Secondary Outcomes
Clinical Outcomes All the subjects were clinically examined
using a standardized neurologic examination, including cen-
tral motor, sensory, cerebellar, cerebral, and peripheral nerve
motor functions. A standard neurologic history and examina-
tionwere used to score the subjects on the Kurtzke EDSS [29].
The 6-minute walk test (6MWT) [30] was performed at all
follow-up visits. For statistical purposes, this test was consid-
ered at 0 versus 12 months.
Evoked Potentials Visual evoked potentials (VEP), brainstem
auditory evoked potentials (BAEP), motor evoked po-
tentials (MEP), somatosensory evoked potentials (SEP),
and laser-evoked potentials (LEP) were obtained through
standard techniques using Synergy electromyographs
(Oxford Instruments, Surrey, UK). Normative data were
obtained from 10 healthy adults examined under the
same experimental conditions [31]. Abnormality was de-
fined as the presence of a latency, amplitude, or con-
duction velocity > 2.5 SD above the mean values in
healthy adults.
Table 1 Clinical and demographic data
PAT Age (years) Sex Dose EDSS MS UL MS LL SPAS UL SPAS LL DTR UL DTR LL CLON UL CLON LL CPR SENS
1 24 M B 6.0 5/5 4/5 1 3 2/4 3/4 – AC EXT AP
2 47 M B 6.0 5/5 5/5 1 2 3/4 3/4 – – EXT N
3 35 M B 1.0 5/5 5/5 1 2 2/4 2/4 – – FLX AP
4 44 M B 4.5 5/5 5/5 1 3 3/4 3/4 – AC EXT AP
5 45 M B 5.0 5/5 4/5 2 3 2/4 3/4 – AC EXT AP
6 37 M B 6.5 5/5 5/5 2 3 2/4 3/4 – + EXT HP
7 51 M B 6.0 5/5 4/5 distal 1 3 3/4 3/4 – AC EXT HP
8 41 M A 6.0 5/5 4/5 1 3 3/4 3/4 – AC EXT HP
9 28 M B 4.5 5/5 4/5 1 2 3/4 3/4 – – EXT HP
10 38 M B 4.0 5/5 4/5 distal 1 2 3/4 3/4 – AC EXT AP
11 37 M B 2.0 5/5 5/5 1 3 3/4 3/4 – + EXT HP
12 64 F B 4.5 5/5 5/5 1 3 2/4 3/4 – – EXT HP
13 31 M B 4.0 5/5 4+/5 distal 1 3 3/4 3/4 – AC EXT HP
PAT = patient; M =male; F = female; EDSS = Expanded Disability Status Scale; MS =muscular strength; UL = upper limbs; LL = lower limbs; SPAS =
spasticity; DTR = deep tendon reflexes; CLON= clonus; AC = achilles clonus; CPR = cutaneous-plantar reflex; FLX = flexor; EXT = extensor; SENS =
sensibility; AP = apallesthesia; HP = hypopallesthesia; N = normal vibratory sensibility
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VEP Monocular pattern reversal VEP was recorded by means
of a pattern reversal black-and-white checkerboard presented
at 1.9 Hz on a cathode ray tube screen. The visual angle was
35′ and 70′. Monocular stimulation was performed by cov-
ering 1 eye with an eye patch, and full-field stimuli were
given. The recording electrode was placed at Oz according
to the international 10/20 system and referenced to Fz.
The ground electrode was placed over the Cz. Signals
were recorded using Synergy electromyographs (Oxford
Instruments) with a bandpass filter set at 1 to 100 Hz, with
a sweep time of 500 ms. At least 2 averages of 100
artifact-free trials were recorded. We measured P100 la-
tency and amplitude.
BAEP BAEPs were obtained for clicks presented at 70 dB
above the hearing threshold using a Synergy electromyo-
graph (Oxford Instruments). A click sound was present-
ed to the unilateral ear on the reference side at a rate of
21.1 Hz using headphones; each side was examined sep-
arately. The bandpass filter was set at 100 Hz to
1.5 kHz. Evoked responses of 1500 stimuli were aver-
aged, and at least 2 trials for each ear were conducted.
The recording electrode was placed over the vertex (Cz),
the reference electrode was placed on the unilateral ear-
lobe, and the ground electrode was placed over the Fz.
The peak latencies of I, II, III, IV, and V waves were
measured, and the interpeak latency between I, III, and
V waves was calculated.
MEP During the magnetic stimulation, the patients lay com-
fortably in a supine position. MEPs were recorded from the
abductor digiti minimi of the hypothenar and abductor
hallucis muscles of the foot using Ag/AgCl surface cup elec-
trodes placed in a belly tendon montage. Signals were record-
ed using Synergy electromyographs (Oxford Instruments)
with filters set at 3 Hz and 10 kHz. Magnetic stimulation
was conducted using a monophasic stimulator (Magstim
200; The Magstim Co. Ltd., UK) and a round magnetic stim-
ulating coil (10-cm diameter; The Magstim Co. Ltd.) to stim-
ulate upper limbs and a double cone coil (11-cm diameter; The
Magstim Co. Ltd.) to stimulate lower limbs. The stimulus was
applied over the vertex of the scalp. To obtain preferential
activation of each hemisphere, induced current flowed from
the posterior to the anterior direction over the motor area. We
measured the threshold for evoking a response in the target
muscles. Responses were recorded at rest and with a minimum
voluntary contraction (facilitation), because MEP size in-
creases and its latency shortens when the muscle is voluntarily
contracted. We recorded 4 consecutive responses at rest and
with facilitation and measured the response with a minimum
latency and maximum amplitude. The central motor conduc-
tion time (CMCT) was calculated with the following formula:
CMCT = CM−((DL + F wave−1) / 2), in which CM is the
latency between the cortex and the muscle explored, DL is
the distal latency of the motor response, and F is the shortest
F wave latency.
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Fig. 1 Trial profile. Patients initially received a lower oral dose A daily
for 2 months (M2). After that, a 2-month washout period was introduced
during which the biomarkers of protein oxidative damage were tested in
plasma (M4). In patients showing normalization of biomarkers (patient
8), the treatment was restarted for 12 months at the same dose (M10,
M16). In patients showing no normalization of oxidative damage
biomarkers, the dosage was increased to dose B for 3 months (M7).
After this treatment period, the biomarkers were tested again during a
new washout period of 2 months (M9). If normalization of the levels
was attained with dose B, the treatment was restarted for 12 more
months with the higher dose (M15, M21). In the eventuality that
protein oxidative damage biomarkers were not reduced, the patient
would have been considered a nonresponder, and the treatment would
have been discontinued at that point. This eventually did not apply to any
of the patients. Blue boxes, patients taking dose A; pink boxes, patients
taking dose B
SEP For SEP recording, patients lay in the supine position in a
warm and semidarkened room to make the patient as comfort-
able as possible and help him to relax. SEPs were elicited after
electrical stimulation (0.2-ms duration, constant current, 4.13-
Hz stimulus rate) with skin electrodes from both median
nerves at the wrist and posterior tibial nerves at the ankle.
The intensity of electrical stimuli was set slightly above the
motor threshold. The number of sweeps averaged was be-
tween 500 and 1000. Samples with excessive interference
were automatically rejected from the average. The EP tracings
were replicated and superimposed to demonstrate the repro-
ducibility of the components measured. The filter bandpass
was 3 to 3000 Hz. The analysis time was 50 ms for median
nerve SEPs and 100 ms for tibial nerve SEPs. Recording elec-
trodes for the median nerve SEPs, with an electrical imped-
ance of less than 4 kΩ, were placed bilaterally in the
supraclavicular fossa (Erb’s point), in the skin overlying the
sixth cervical spinous process (Cv6) and in the parietal scalp
region (C3′ and C4′). The Erb’s point electrode was referred to
the contralateral Erb’s point, the Cv6 electrode was referred to
an electrode located immediately above the thyroid cartilage
and scalp electrodes (C3′ and C4′) were referred to Fz. For the
posterior tibial nerve SEPs, the recording electrodes were
placed over the tibial nerve in the popliteal fossa, over the
low back on the skin overlying the spinous processes of ver-
tebra L1, over the skin overlying the cervical spine and in Cz′
(2 cm posterior to the Cz) in the scalp. The popliteal fossa
electrode was referred to an electrode placed 3 cm proximally,
the first lumbar vertebra electrode was referred to an electrode
located immediately above the umbilicus, the Fz electrode
was referred to cervical electrode, and Cz′ was referred to
Fz. For median nerve SEPs, we evaluated peaking latencies
of Erb’s point N9, generated by the brachial plexus volley and
recorded by the Erb’s electrode; the spinal N13 response, gen-
erated within the cervical gray matter; and contralateral scalp
N20, recorded from the parietal electrode and generated in the
primary somatosensory (SI) area. We also calculated N9-N13,
N9-N20, and N13-N20 interpeak latencies and measured the
peak-to-peak amplitude between N20 and the subsequent pos-
itive peak (P25). For tibial nerve SEPs, we evaluated the
peaking latencies of the N8 recorded at the popliteal fossa,
N22 recorded at L1 generated by the lumbosacral dorsal horn
neurons, P30 recorded at the sixth cervical spinous process,
and the scalp P40 response, probably generated in the SI area.
We also calculated N22-P40 to assess the conduction time in
central somatosensory pathways and measured the peak-to-
peak amplitude between P40 and the subsequent negative
peak (N50).
LEP LEPswere obtained by delivering brief radiant heat pulses
to the face, dorsum of the hand and leg by means of a NdYAP
laser stimulator (wave length 1.34 μm; beam diameter 5 mm;
energy 1.5–3.5 J; duration 5 ms). The stimulus intensity was
approximately 1.5 to 2 times the mean pain threshold of
healthy subjects. Signals were recorded using a Synergy elec-
tromyograph (Oxford Instruments). LEPs were recorded from
Cz with reference to linked earlobes, using silver/silver chlo-
ride cup electrodes of 9-mm diameter filled with a conductive
adhesive gel. The amplifier bandpass frequency filter was 0.2
to 100 Hz. The analysis time was 1 s. Impedance was main-
tained at less than 4 kΩ. Ten artifact-free LEPs were recorded
for each side and averaged offline.Wemeasured the latency of
the first negative peak (N2) and of the subsequent positive
peak (P2), as well as the peak-to-peak amplitude (N2/P2
amplitude).
Nerve Conduction Studies Synergy electromyographs
(Oxford Instruments) were used for these studies. The fol-
lowing parameters were measured: nerve conduction ve-
locity, distal latency (with the distance kept constant), and
amplitude of response. Recordings were performed using
standard methods [32]. Abnormality was defined as the
presence of a latency, amplitude, or conduction velocity
> 2 SD or 1 SD. In motor nerve conduction studies, at
least 1 unilateral median, ulnar, and peroneal nerve was
evaluated. Distal and proximal compound muscle action
potential (CMAP) amplitude, distal motor latency (DML),
duration of proximal and distal CMAP (dCMAP), and
motor nerve conduction velocity (MNCV) were also
assessed. The sensory tests were performed in the sural
nerve, except in 1 patient (patient 7), who had suffered a
previous bilateral sural biopsy. In this patient, the studies
were performed in the superficial peroneal nerve. The mo-
tor nerve conduction studies were performed in the pero-
neal nerve except for patient 1, for whom the studies were
performed in the tibial nerve. With regard to these studies,
7/13 subjects presented a mild peripheral neuropathy at
the beginning of the trial. A pattern suggestive of neurop-
athy with demyelinating features was observed in 2/13
subjects, and axonal neuropathy in 5/13 subjects.
MRI OutcomesMRI with gadolinium contrast was performed
in a 1.5-T apparatus (Philips Healthcare, Best, The Netherlands).
Diffusion tensor imaging (fractional anisotropy maps) was
obtained for each patient. Sagittal T1-weighted, coronal-
enhanced IRT1-weighted imaging, and FLAIR sequences
were obtained for the axial plane and coronal sequences
with pulse inversion recovery providing high contrast be-
tween white matter lesions and other adjacent structures.
The subjects were classified into 3 groups according to
severity of the lesions in FLAIR/T1 images. Three subjects
(3, 8, and 9) showed a normal pattern, 7 exhibited moder-
ate lesions in the corticospinal tract (CST) and peritrigonal
white matter (mild hyperintensity on FLAIR sequence,
with a bilateral and symmetrical distribution), and 3 (sub-
jects 1, 4, and 6) exhibited clearly pathological lesions in
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the CST. In those 3 subjects, the lesions were more severe in
the internal capsule and midbrain, peritrigonal white matter,
optic radiation, and corpus callosum; in addition, the pattern
of lesions was more focal, with prominent altered signals.
DTI was acquired using a single-shot sequence echo planar
imaging. The image matrix was 144 and a field of vision
(FOV) of 234 × 170 mm was the direction of phase AP. The
entire skull was studied, including stem, with 60 axial sections
2 mm thick, which were acquired parallel to the anterior and
posterior white matter commeasured with isometric voxel 2 ×
2 × 2 mm. The value of b was 400 to 800 s/mm2 with an
average resolution, and 16 points were calculated. From this
sequence, the isotropic image and fractional anisotropy (FA)
maps for each of the patients were obtained. Regions of inter-
est (ROIs) were defined coinciding with MRS voxel, and the
FA values were obtained at the bilateral corticospinal tract. A
third ROI was performed in 3 patients in whom impaired
signal was observed in the white matter on conventional se-
quences. Visual inspection of the diffusion images was per-
formed to exclude moving images or artifacts. The single-
voxel 1H-MRS technique was used to acquire data from
MRS. A VOI from 1.5 to 2 cm3 was placed in the left
parieto–occipital white matter. Two spectra were acquired in
the same VOI: 1) SE STE (TR/TE/stockings, 2000/30/96 -
192) and 2) (TR/TE/averages, 2000/136/128-256) SE LTE.
Myo/Cr, Cho/NAA, and NAA/Cr ratios were calculated for
each patient. The same radiologist performed the evaluation of
the images and calculations consecutively.
Safety Outcomes Two patients were removed from the statis-
tical analysis. Subject 1, who showed a more severe lesion
pattern on MRI among the patients, presented a behavioral
change after 9 months in the trial, with a jocular attitude,
puerility, and impulsiveness, signs of frontal release (glabellar
and palmomental reflexes), and developed inflammatory le-
sions 6 months after the end of the treatment. Subject 6 pre-
sented hypomania, perseveration, and disinhibition, as previ-
ously noted in the pre-existing medical history, although the
principal investigator considered during the inclusion period
that he would be able to follow through with treatment.
Although the development of psychiatric disease and cerebral
manifestations is common in AMN, because we did not in-
clude an untreated comparison group, we cannot formally
exclude an unlikely treatment-related event. Furthermore, the
low number of patients and short observation period in our
cohort preclude from extrapolating howmanywould be expect-
ed to develop the cerebral AMN phenotype in our cohort.
Statistical Analysis
Protein oxidative damage, inflammation biomarkers, and Q-
PCR array expression data were examined for normality by
the Shapiro–Wilk test. Significant differences were
determined using a 1-tailed Student’s T test if the data were
normally distributed or a 1-tailed Wilcoxon rank sum test
otherwise. When analyzing the treatment effect by compar-
ing patient scores at different time points, we used the 1-
tailed paired Student’s T test if the data were normally
distributed or the 1-tailed Wilcoxon signed rank test other-
wise. We chose the 1-tailed T test instead of the 2-tailed
because we aimed to elucidate whether or not the analyzed
parameter deviated from the controls in the same sense for
all subjects. We further analyzed whether these values were
affected by the treatment and changed in concert as a block
in a given sense. The patient on dose Awas excluded from
the statistical study, as the dose used was much lower than
the rest of patients.
Principal component analysis (PCA) was applied as
previously reported [33]. We performed 3 different anal-
yses grouping the variables under the following catego-
ries: 1) clinical variables and 2) expression levels of in-
flammatory markers and mediators. We considered those
factors that changed significantly in response to treat-
ment, and we analyzed their levels prior to treatment as
variables, together with the age of the patients. To extract
the eigenvalues and calculate the factor loadings, PCA
was performed with the S-Plus princomp function in
the R programming environment.
Penalty regression methods were conducted using the
glmnet package [34] in R. Briefly, we applied a likelihood
ratio test using the lmtest package [35] to differentiate the
influence of the variables selected by the penalty regres-
sion methods from confounding variables such as age and
distance walked in the 6MWT before treatment [36]. The
statistical analyses were performed using the Bioconductor
packages in the R programming environment [37]. To in-
vestigate whether the distance walked at the end of the
assay in the 6MWT could be predicted by the levels of
oxidative damage and inflammatory markers, we distribut-
ed the data into 3 groups of variables: i) inflammatory
cytokines, chemokines, and receptors; ii) inflammation-
associated lipids; and iii) the expression of inflammatory
cytokines, chemokines, and receptors. We also included
the age and 6MWT distance for each patient before treat-
ment as independent variables. We applied Y = b0 + b1X1 +
b2X2 … bnXn to the independent variables (X1… Xn), which
were defined as the 6MWT distance before treatment, age,
MCP1, and 15S-HETE levels, to better predict the depen-
dent variable (Y), i.e., the 6MWT distance at the end of the
study. To validate the penalized regression model, the anal-
ysis included a leave-one-out cross-validation (LOOCV)
procedure characterized by using a single sample as vali-
dation data for testing the model, whereas the remaining
samples were utilized as training data. The cross-validation
process was then repeated as many times as the number of
samples used in the model [38].
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Results
Primary Outcomes
A main purpose of this study was to identify and validate
robust biomarkers to monitor the biological effects and effica-
cy of the proposed combination of antioxidants, and thereby
lay groundwork for future, larger trials with drugs targeting
redox or inflammatory homeostasis.
Oxidative Stress Markers Our primary objective aimed to pin-
point a dose of antioxidants that was safe and biologically
active to normalize the quantitative markers of oxidative dam-
age to proteins previously tested in a small number of patients
with AMN [39], hence validating these biomarkers. We also
included a well-characterized marker of oxidative damage to
DNA, 8-oxo-dG, which is currently broadly used for neuro-
degenerative disorders [40, 41].
At baseline, we observed a significant increase in CML,
CEL, MDAL, and 8-oxo-dG levels (in plasma and urine, re-
spectively) and a trend towards higher AASA levels in the
plasma of AMN patients compared with sex- and age-
matched controls, with CEL levels being the best discriminat-
ing factor of genotype (Fig. 2a). After treatment with dose A
(2 months), the levels of AASA and 8-oxo-dG did not vary,
with the exception of patient 8, who showed normalized
levels. The remaining subjects received dose B after a washout
period of 2 months, and this higher dose was found to drasti-
cally decrease all oxidative damage markers after 3 months of
use (Fig. 2b). Patient 12, the only female patient included in
the study, presented similar values to those detected in male
patients.
Inflammatory Markers We had previously used an integrated
omics approach in plasma and PBMCs of patients with AMN,
identifying several molecules of potential interest [27].
Patients with AMN exhibited significantly higher plasma
levels of the lipid mediators of inflammation, 12S-HETE,
15S-HETE, and TXB2, as well as the cytokines and
inflammation-related proteins, IL-6, TNF, IL-8, HGF, and
MCP1, and lower levels of the protective protein adiponectin.
At the mRNA level, we also reported significant overexpres-
sion of the inflammatory markers IFNA2, IL-37, IL-4, IL-10,
IL-9R, IL-36RN, IL-36A, IL-13, CCR3, CXCL5, and STAT1
[27]. Here, we could validate these molecules in an indepen-
dent cohort, and we found that antioxidant treatment signifi-
cantly decreased the levels of pro-inflammatory IFNA2, IL-4,
IL-36A, and CCR3 in PBMCs, and 12S-HETE, 15S-HETE,
TXB2, TNF, and IL-8 in plasma, and increased those of anti-
inflammatory plasma adiponectin relative to pretreatment
levels. In a similar manner, the treatment further increased
the already-high levels of the anti-inflammatory cytokine IL-
10 in PBMCs. In addition, we also tested neopterin, a sensitive
marker of immune system activation for neurodegenerative
disorders such as Parkinson’s disease [42], which was not
previously reported in X-ALD. We found elevated levels of
neopterin in the CSF before treatment; these levels were sig-
nificantly decreased with antioxidant treatment in all the sub-
jects from whom CSF was available (Fig. 3).
Safety Outcomes Both high and low doses of the combination
of antioxidants were safe and well-tolerated. Four sub-
jects experienced mild adverse events during the trial in
relation to mild and transient constipation and responded
well to conservative dietary treatment. Subjects 1 and 6
interrupted the treatment after 9 and 3 months, respec-
tively, because the principal investigator had doubts re-
garding fulfillment of the treatment given their behavioral
compromise.
Secondary Outcomes
Clinical Outcomes Because disturbances in walking and gait
are key components of the AMN clinical presentation,
ambulation-related outcome measures were chosen as the
most relevant clinical endpoints. The 6MWT is considered
an accurate, reproducible, simple-to-carry out, well-toler-
ated, and well-established outcome measured in a variety
of diseases [30]. Importantly, the 6MWT assesses function
and endurance, which are important aspects of AMN dis-
ease status. Before treatment, we observed a strong inverse
correlation between the EDSS and 6MWT distance
(Pearson’s correlation, 0.8; associated probability =
0.001). According to the patient distribution in this corre-
lation representation (Fig. 4a), we therefore grouped the
subjects into 3 clinical phenotypes: mild (EDSS between
1 and 2 and high 6MWT distances) (gray), moderate
(EDSS between 3 and 4.5 and intermediate 6MWT dis-
tances) (yellow), and severe (EDSS between 4.5 and 6
and low 6MWT distances) (blue) (Fig. 4a). At the end of
the study, the EDSS scores remained stable in all subjects.
However, we found an overall significant improvement of
the distance walked in the 6MWT that varies depending on
the clinical status of the patients at M0 (Fig. 4b). The dis-
tance walked increased in 8 subjects, did not change for 1
patient, and worsened by 20% in patient 7 (Fig. 4c).
Subjects with a more severe presentation improved be-
tween 20 and 60% (subjects 2, 5, and 12), those in the
moderate group improved slightly (5–15%, subjects 9,
10, and 13), and those with a milder presentation improved
less than 5% (subjects 3, 11) (Fig. 4b, d).
Electrophysiological OutcomesAll the subjects presented with
alterations in MEP and BAEP, 10/11 presented with dis-
turbances in SEP, and 1/13 in VEP at baseline [31]. We
also measured LEP, which provides a direct functional
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examination of the nociceptive afferents, particularly
neuropathic pain [43]. We found that LEP signals in-
creased in 8/13 subjects [31]. After 12 months of treat-
ment with antioxidants, although the values were still
above normal, we detected a significant decrease in the
central motor conduction time of MEP in both legs, thus
reflecting a slight improvement in upper motor neuron
function (paired t test, right p = 0.0096, left p = 0.0178)
(Fig. 4e). The rest of the evoked potentials remained
statistically unchanged, although 1 patient exhibited
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normalized LEPs after treatment (details in Tables 2a, b
in Supplemental Data). Regarding nerve conduction stud-
ies, none of the subjects exhibited differences in these
values with respect to baseline after 1 year of antioxi-
dants (details in Table 3 in Supplemental Data).
MRI Outcomes DTI analysis revealed that all the subjects ex-
hibited lower fractional anisotropy (FA) values in the bilateral
corticospinal tract, in particular patients 6, 7, and 10 at
baseline, although the differences were not significant
statistically. At the end of the antioxidant treatment, no
significant differences were observed (details in Table 4
in Supplemental Data).
Stratification of Subjects by Integrating Biomarkers
and Clinical Variables
We applied PCA to examine whether subjects with AMN
could be stratified into subgroups according to their clinical
severity. Figure 5 shows the relationship among specific bio-
markers, which are represented as a vector, and the patient’s
distribution with respect to these vectors according to the bio-
marker values of each patient prior to treatment (baseline,
M0). We observe that patient distribution matches the pheno-
type classification as defined previously in Fig. 4a, in groups
according to severe (blue), moderate (yellow), and mild (gray)
EDSS scores/6MWT at M0. In this sense, we can see in
Fig. 5a how the distance measured at 6MWT correlates in-
versely with age and EDSS. We also see how the most severe
patients with higher EDSS (2, 5, and 7) are distributed towards
the end of the EDSS vector and how mild patients (3 and 11)
are located near the end of the 6MWT vector. In Fig. 5b, the
most severe patients are distributed towards the end of their
vectors representing the pro-inflammatory markers MCP1,
TNF, or IL-8, whereas the milder patients (3 and 11) are just
at the opposite end of their vectors. This means that, taken
together, the consideration of the levels of MCP1, TNF, and
IL-8 helps to stratify the patients according to clinical severity.
Patient 7, who showed a severe phenotype, is an exception,
but it is worth noting that he did not improve in the 6MWT
(Fig. 5b). We also observed that subjects in the mild subgroup
presented with higher IL-10 levels (patients 3 and 11) (Fig.
5c). Remarkably, the treatment did not normalize the anti-
inflammatory cytokine IL-10 but instead increased its expres-
sion, thus suggesting that the regulation of IL-10 involves
redox-sensitive mechanisms and may be protective in the X-
ALD context.
Association of MCP1 and 15S-HETE with the 6MWT
We applied penalized regression methods to investigate
whether the distance walked at the end of the study
(M21) in the 6MWT could be predicted by the levels of
oxidative damage and inflammatory markers, either at
baseline or at M7. Figure 6 shows the models with a max-
imum of 2 predictors that best fitted the clinical outcomes.
We present 2 different models in Fig. 6a (model 1 and
model 2), which consider the 6MWT before treatment at
M0, and the MCP1 ratio levels at the M7/M0, or the 15S-
HETE levels at the M7 visit, respectively, as independent
variables. A significant inverse association was observed
between the MCP1 ratios (M7 visit/M0), and the distance
walked in the 6MWT for each patient, compared with his
own baseline. These results indicated that subjects who
showed a more prominent decrease in MCP1 levels at
M7 also showed a more marked improvement in walking
distance at the end of the treatment. The goodness of fit of
the model is confirmed by the very significant Pearson
correlation between the predicted and the real meters
walked at the M21 (Pearson ’s correlat ion, 0.97;
P = 6.14E−06), Fig. 6a, b. Another model that was suc-
cessful in predicting 6MWT improvement was the one that
included the 15S-HETE levels at the M7 visit (Pearson’s
correlation, 0.95; P = 6.59E−05) (Fig. 6a, c). Specifically,
15S-HETE levels at M7 were inversely proportional to the
improvement in distance walked in the 6MWTat the end of
the study. This result indicated that the lower the levels of
the MCP1 ratio or 15S-HETE levels at M7, the more im-
portant the amelioration in walking capacity at the end of
the study. In other words, 15S-HETE and, in particular,
MCP1 ratios are predictive of response to treatment, both
positive and negative. It is worth noting that the levels of
none of the single biomarkers at M0 are significantly as-
sociated with the clinical status, neither at M0 nor with the
improvement in the 6WMT at M21. We have found that the
MCP1 or the 15S-HETE levels standing alone are insuffi-
cient to predict the clinical efficacy of the treatment. The
clinical status of the patient at baseline (6MWTat time M0)
needs to enter the equation as well, as deduced from the
statistical analysis using penalized regression models. On
the other hand, the p value of the likelihood ratio test (LRT,
Fig. 6a) indicates that the 6MWT at M0 standing alone is
Fig. 2 Oxidative lesion markers and treatment effect in subjects. (a)
Significant pretreatment increase in the oxidation markers CML, CEL,
MDAL in the plasma, and 8-oxo-dG in the urine is observed in subjects
compared with controls. Whiskers indicate 1.5 times the interquartile
range; the bottom and top of the boxes indicate the first and third
quartiles, respectively; the center lines of the boxes indicate the second
quartile. (b) A significant decrease was observed in the plasma
concentrations of the oxidation markers CML, CEL, and MDAL after
2 months with dose A (M2) and, more strikingly, after 3 months with
dose B (M7) compared with pretreatment levels at the initial time point
(M0). A significant decrease in AASA in plasma and urine 8-oxo-dG
levels was only observed after 3 months with dose B. P values are
colored red if they are less than 0.05. AASA, CML, CEL, and MDAL
are expressed as μmol/mol lysine; 8-oxo-dG is expressed as ng/mg
creatine
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less powerful predicting the 6MWT at M21 than the com-
bination of 6MWT at M0 plus the MCP1 ratios. The same
is true for model 2 including 15S-HETE, although, in this
case, it does not reach statistical significance, indicating
that model 1 is the most robust predictive model in this
set of patients.
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Fig. 3 Effects of the antioxidant treatment on inflammatory markers. (a)
A significant decrease was observed in the pro-inflammatory markers
12S-HETE, 15S-HETE, TXB2, TNF, IL-8, IFNA2, IL-36A, and CCR3
after 3 months with dose B compared with pretreatment levels. (b) A
significant increase was detected in the levels of the anti-inflammatory
markers adiponectin and IL-10 after 3 months with dose B comparedwith
pretreatment levels at the initial time point (time 0). The same treatment
led to a significant decrease in IL-4 levels. (c) Significantly higher levels
of neopterin in cerebrospinal fluid andMCP1 in plasma were observed in
AMN patients before treatment, and neopterin levels exhibited a
significant decrease after 3 months of treatment. Whiskers indicate 1.5
times the interquartile range; the bottom and top of the boxes indicate first
and third quartiles, respectively; the center lines of the boxes indicate the
second quartile. P values are colored red if they are less than 0.05. The
12S-HETE, 15S-HETE, and TXB2 in plasma and neopterin in
cerebrospinal fluid are expressed as μmol/l; TNF, IL-8, and MCP1 in
plasma are expressed as pg/ml; adiponectin in plasma is expressed as
μg/ml; IFNA2, IL-36A, CCR3, IL-4, and IL-10 are expressed as the
relative gene expression in PBMCs
Discussion
This open-label trial was primarily envisaged to translate the
positive preclinical results obtained on a mouse model of
adrenomyeloneuropathy treated with the same combination
of antioxidants, by identifying a safe, well-tolerated dose that
would achieve biological efficacy in patients. The design also
aimed to identify and validate meaningful biomarkers to mon-
itor biological efficacy or target engagement to guide larger,
randomized placebo-controlled studies. We believe this
objective was successfully achieved and provide herein a pan-
el of quantitative oxidative lesion markers and lipid inflam-
matory mediators in the plasma, cytokines in the plasma and
PBMCs, neopterin in the CSF, and 8-oxo-dG in the urine,
which may be useful for monitoring future treatments and
disease progression. Most importantly, we report the normal-
ization of several inflammation markers upon antioxidant
treatment, in addition to markers of oxidative damage, indi-
cating that redox and inflammatory homeostasis are deeply
intertwined in this disease.
Fig. 4 Effects of treatment on the
6-minute walk test (6MWT) and
on motor evoked potentials. (a)
The correlation between the
6MWT and EDSS before
treatment at the initial time point.
(b) The correlation between the
6MWT and EDSS at the end of
treatment. In (a) and (b), the
colors represent the 3 different
phenotypes: mild in gray,
moderate in yellow, and severe in
blue. Subjects with an
improvement are represented by
darker colors. The correlation was
measured using Pearson’s product
moment correlation coefficient
test. (c) Significant improvements
were observed in the distance
walked in the last visit compared
with the pretreatment distances.
Eight subjects improved in the
distance walked, 1 showed no
change and 1 worsened. (d) The
percentage of improvement of
subjects in the 6MWT is
indicated. Only subjects with
amelioration of their scores are
listed. n = number of cases of each
phenotype. (e) A significant
decrease was observed in central
motor conduction time (CMCT)
in both legs in the last visit in
comparison with baseline. R =
right; L = left. P values are
colored in red if they are less than
0.05. CMCT is the difference
between the shortest peripheral
motor and the shortest
corticomotor latencies
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Indeed, the pro-inflammatory derivatives of arachidonic
acid (TBX2, 12S-HETE, and 15S-HETE) and several pro-
inflammatory cytokines and chemokines (IL-8, TNF,
IFNA2, IL-4, IL-36A, and CCR3) exhibited greatly de-
creased or normalized values after the antioxidant treat-
ment. Of note, the treatment increased the levels of the
protective cytokine adiponectin, which was previously re-
ported to be significantly diminished in a small cohort of
subjects with AMN [27] and a mouse model [44].
Furthermore, antioxidant treatment increased the already-
elevated levels of the anti-inflammatory cytokine IL-10,
suggesting a protective effect of the antioxidants in this
series. Although AMN has long been considered to be a
non-inflammatory disorder—as opposed to cerebral child-
hood ALD or adult-onset cerebral AMN—mounting evi-
dence indicates that pro-inflammatory cascades are signif-
icant although controlled under tight regulatory cues [27].
On this pro-inflammatory background, which may repre-
sent the “default form” of the disease, additional genetic or
environmental hits, such as brain trauma, may provoke
conversion to the rapidly progressive and lethal cerebral
ALD or AMN forms [45].
In this trial, we have learned that redox homeostasis is
directly linked to inflammatory status in this disease, so
that antioxidants may help to ameliorate the chronic, low-
grade pro-inflammatory state that characterizes AMN and,
as a consequence, modify or slow disease progression. It
is tempting to speculate that our results may strengthen the
rationale for the improved outcomes of hematopoietic
stem cell transplantation in the presence of NAC [46]
and argue for the use of antioxidants as a companion treat-
ment also for the most severe cerebral inflammatory forms
of the disease, cALD. In addition, using penalized regres-
sion methods, we discovered markers with predictive val-
ue for the response to treatment. Indeed, the levels of
MCP1 negatively affected the percentage of improvement
in the walked distance in the 6MWT, indicating that sev-
eral subjects showed a correlation between an improve-
ment in walking distance and a decrease in MCP1 levels
following treatment. The reverse was also true for patient
7, who showed increased MCP1 levels and a poorer
6MWT result in the final visit. Thus, the response of
MCP1 to the antioxidant treatment (by decreasing its
levels in comparison with baseline) may be considered a
candidate predictor of disease progression in this cohort.
Of note, MCP1 has been shown to be increased in the CSF
of children with cALD [47], underscoring the interest in
this biomarker across discordant disease phenotypes. This
chemokine is the most potent inducer of the signal trans-
duction pathways leading to monocyte transmigration [48,
49], and accumulating evidence suggests that MCP1 and
its receptor, CCR2, may be prime targets to combat neu-
roinflammation [50]. The same conclusion applies to 15S-
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Fig. 5 Stratification of patients by integrating biomarkers with clinical
variables. PCA was used to distribute patients with AMN according to
their clinical phenotype severity (in (a)) and according to their
pretreatment biomarker values (b, c). Loading plots: the axes for
components 1 and 2 indicate the most varying direction of the data, and
the arrows show the direction of the variables. Mild phenotypes are
shown in gray, moderate phenotypes in yellow, and severe phenotypes
in blue. Darker colors depict patients who improved clinically in the
6MWT after treatment. In (a), the clinical variables EDSS and 6MWT
are shown in relation to age. In (b), the plasma levels of inflammatory
molecules in relation to age are shown. The most severe phenotypes show
higher levels of MCP1, TNF, and IL-8, except for patient 7. In (c), the
expression of molecules and mediators of inflammation in PBMCs are
shown. Patients 3 and 11, with milder phenotypes, showed higher levels
of protective IL-10
HETE, a lipid mediator of inflammation and potent ago-
nist of PPARbeta/delta receptors [51, 52], which showed
an inverse correlation with an improvement in walking
distance in this series. Thus, confirmation of the predictive
value of MCP1 and 15S-HETE in additional, larger co-
horts is warranted.
With all the natural, obliged reservation that emanates
from a small open trial, it is intriguing that the treatment
appeared to confer a statistically significant clinical benefit
in several parameters. We detected a significant improve-
ment in 6MWT, particularly in subjects with higher EDSS
scores. The 6MWT appeared to be sufficiently sensitive to
discern any possible differences in the distances walked
and to be a good clinical outcome measure for the
follow-up of moderately or severely affected subjects dur-
ing the treatment.
Although a placebo effect cannot be excluded, the robust
improvements in several biological outcomemeasures, as well
as some mild but statistically significant amelioration in inde-
pendent clinical and neurophysiological outcomes, may sug-
gest an intriguing positive signal. Furthermore, this work pro-
vides a series of markers to monitor the biological effects of
prospective trials, some of which, such as MCP1, have the
potential to correlate with disease progression and clinical
efficacy. Likewise, the 6MWT may be meaningful to monitor
the clinical treatment efficacy. The observed tolerability, safe-
ty, and signs of clinical benefit of this pilot study may warrant
the long-term use of these or other next-generation antioxi-
dants [53] in a phase III, double-blind, randomized, placebo-
controlled clinical trial with a larger number of subjects. The
safety and tolerability of the doses used may facilitate exten-
sion of similar antioxidant combinations to other diseases that
share both axonal degeneration as a significant component of
clinical progression and redox imbalance as a primary or early
contributing pathogenic factor [54, 55].
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